Hence, the findings implied that miR‐100‐5p targets IGF1R, thereby inhibiting PI3K/AKT pathway activation, and thus inhibits lymphangiogenesis in ESCC. The gene discussed is AKT1; the disease is esophageal squamous cell carcinoma.